Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PACIFICA Phase 3
2024-515953-52-00Phase 3Authorised
- Sponsor
- Sobi
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, open-label trial of pacritinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and myelofibrosis (MF) (2 arms), sponsored by Sobi. Primary endpoints: Spleen volume response at Week 24 and Symptom response at Week 24. Planned start Jul 2020; status: authorised.
02
Drugs
pacritinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)myelofibrosis (MF)
Beyond the preview
Go deeper on 2024-515953-52-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-515953-52-00.